Sorrento's proprietary G-MAB thev naus laus zis, tsim los ntawm Dr. Ji, yog raws li kev siv RNA transcription rau kev nthuav dav ntawm cov tshuaj tiv thaiv kab mob sib txawv los ntawm ntau dua 600 tus neeg pub dawb. 

Kev soj ntsuam tob tob ntawm cov ntaub ntawv DNA sib sib zog nqus tau pom tias G-MAB lub tsev qiv ntawv muaj ntau dua 10 plaub npaug (10¹⁶) cov tshuaj tiv thaiv kab mob sib txawv. Qhov no ua rau nws yog ib lub tsev qiv ntawv loj tshaj plaws ntawm tib neeg cov tshuaj tiv thaiv kab mob hauv kev lag luam biopharmaceutical. Txog tam sim no, Sorrento tau ua tiav cov txiaj ntsig ntawm tib neeg cov tshuaj tiv thaiv tawm tsam ntau dua 100 qhov chaw kho mob muaj feem cuam tshuam rau cov kab mob oncogenic, suav nrog PD-1, PD-L1, CD38, CD123, CD47, VEGFR2, thiab CCR2.

Kev tshuaj ntsuam xyuas tau zoo heev (100+ soj ntsuam cov hom phiaj cuam tshuam).

• Kev sib txawv heev (2 x 10¹⁶ txawv antibody sequences)
• Proprietary technology (RNA amplification rau tsev qiv ntawv tiam)

Manufacturing Peev Xwm:

• cGMP qhov chaw
• Fill/finish peev xwm
• Kev them nyiaj yug analytical tag nrho